Erlotinib

Manufactured by LC Laboratories

Sourced in United States, United Kingdom, Germany

Erlotinib is a laboratory product available from LC Laboratories. It is a small-molecule tyrosine kinase inhibitor.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Erlotinib hydrochloride (10 citations) Erlotinib-HCl (3 citations) Erlotinib hydrochloride salt (3 citations)

93 protocols using erlotinib

Establishing EGFR-TKI Resistant NSCLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

H1299, H1975, and PC9 human NSCLC cell lines were kind gifts from Professor Ho-Young Lee (Seoul National University, Seoul, Korea). RPMI-1640 (WelGENE, Daegu, Korea) with 10% fetal bovine serum (FBS; WelGENE, Daegu, Korea) and 1% antibiotics (WelGENE, Daegu, Korea) was used as the culture medium. The cells were sub-cultured every three days and maintained at 37 °C under 5% CO₂. Erlotinib-resistant PC9 (PC9/ER) and gefitinib-resistant PC9 cell lines (PC9/GR) were established by exposing PC9 cells to increasing concentrations of Erlotinib (LC Laboratories, Woburn, MA, USA) or gefitinib (Cayman Chemical, Ann Arbor, MI, USA). The PC9 cells were treated with 0.1 μM of Erlotinib or gefitinib as a starting concentration. The culture medium was changed to fresh medium every three days until the cells reached confluence. The cells were then incubated with gradually increasing concentrations of EGFR TKIs for four months. The final concentrations of the drugs were 50 μM for Erlotinib and 25 μM for gefitinib. The PC9/ER and PC9/GR cell lines were cultured in medium containing Erlotinib (25 μM) or gefitinib (12.5 μM), respectively.

Park H.J., Park S.H., Choi Y.H, & Chi G.Y. (2021). The Root Extract of Scutellaria baicalensis Induces Apoptosis in EGFR TKI-Resistant Human Lung Cancer Cells by Inactivation of STAT3. International Journal of Molecular Sciences, 22(10), 5181.

+ Open protocol

+ Expand

Evaluating IGF-1 Signaling Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

des[1–3]IGF-1 (desIGF1) is an N-terminally truncated form of IGF-1 that does not bind appreciably to IGF binding proteins (IGFBPs). It was obtained from Cell Sciences (Canton, MA) and used to mitigate any effect of secreted IGFBPs in vitro. AlamarBlue, DMEM/F-12 media with HEPES, and fetal bovine serum were obtained from Invitrogen (Carlsbad, CA). Lapatinib was obtained from Chemietek (Indianapolis, IN), and gefitinib and erlotinib from LC Laboratories (Woburn, MA). Anti-IGF1R was acquired from Santa Cruz Biotechnology, anti-Akt, anti-p-Akt (T308), anti-p-Akt (S473), anti-PRAS40, anti-p-PRAS40 (T246), anti-p70S6K, anti-p-p70S6K (T389), anti-p-IGF1R, anti-FOXO3a, and anti- β-actin from Cell Signaling Technology (Beverly, MA).

Dougherty M.I., Lehman C.E., Spencer A., Mendez R.E., David A.P., Taniguchi L.E., Wulfkuhle J., Petricoin E.F., Gioeli D, & Jameson M.J. (2020). PRAS40 phosphorylation correlates with insulin-like growth factor-1 receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer cells. Molecular cancer research : MCR, 18(9), 1392-1401.

+ Open protocol

+ Expand

Comparative Analysis of EGFR Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Erlotinib and afatinib were purchased from LC Laboratories (Woburn, MA, USA). Osimertinib and rociletinib were purchased from Selleck Chemicals (Houston, TX, USA). Total EGFR antibody (#2232), total AKT antibody (#9272), phospho-AKT (S473; D9E) antibody (#4060), total p44/42 MAPK antibody (#9102S), and phospho-p44/42 MAPK (T202/204) antibody (#9101S) were purchased from Cell Signaling Technology (Beverly, MA, USA). Phospho-EGFR (Y1068) antibody (44788G) was purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Actin antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA).

Hirano T., Yasuda H., Tani T., Hamamoto J., Oashi A., Ishioka K., Arai D., Nukaga S., Miyawaki M., Kawada I., Naoki K., Costa D.B., Kobayashi S.S., Betsuyaku T, & Soejima K. (2015). In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget, 6(36), 38789-38803.

+ Open protocol

+ Expand

Molecular Mechanisms of Honokiol in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Honokiol (≥ 98% of purity) was purchased from LKT laboratories (Minneapolis, MN). Anti-phospho-EGFR (Y1068), anti-total EGFR, anti-phospho-Akt (S473), anti-total Akt, anti-phospho-ERK (T202/Y204), anti-total ERK, anti-phospho-STAT3 (Y705), anti-total STAT3, anti-cyclin D1, anti-CDK2, anti-CDK4, anti- phospho-Rb (S807/811), anti-p27, anti-caspase 3, anti-phospho-GSK3α/β (S21/9), anti-IκBα, anti-bax, anti-phospho-Bad, anti-β-actin, anti-caspase 8, anti-caspase 9 and goat anti-rabbit IgG secondary antibody were from Cell Signaling Technology (Beverly, MA). Anti-poly (ADP-ribose) polymerase (PARP) and anti-p21 were obtained from Santa Cruz Biotechnology. Erlotinib (99% of purity) was purchased from LC Laboratories (Woburn, MA). NNK (99% of purity) was synthesized as described elsewhere [60 (link)].

Song J.M., Anandharaj A., Upadhyaya P., Kirtane A.R., Kim J.H., Hong K.H., Panyam J, & Kassie F. (2016). Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget, 7(36), 57752-57769.

+ Open protocol

+ Expand

EGF-Mediated Regulation of PD-L1 Turnover

Check if the same lab product or an alternative is used in the 5 most similar protocols

Osimertinib was purchased from Active Biochemicals (Maplewood, NJ). Erlotinib was purchased from LC Laboratories (Woburn, MA). CO1686 was purchased from MedChemExpress USA (Monmouth Junction, NJ). Actinomycin D (Act D), cycloheximide (CHX), and MG132 were purchased from Sigma Chemical Co. (St. Louis, MO). These reagents were dissolved in DMSO at the concentration of 10 mM as stock, which were aliquoted and stored at −80°C before use. Recombinant human EGF and INF-γ protein were purchased from R&D Systems (Minneapolis, MN) and prepared according to product instructions. Rabbit anti-human (E1L3N) and mouse anti-human PD-L1 (405.9A11) antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA). MARCH8 and GAPDH antibodies were purchased from Proteintech (Rosemont, IL). Mouse monoclonal anti-β-actin and anti-tubulin antibodies were purchased from Sigma Chemical Co.

Qian G., Guo J., Vallega K.A., Hu C., Chen Z., Deng Y., Wang Q., Fan S., Ramalingam S.S., Owonikoko T.K., Wei W, & Sun S.Y. (2021). Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. Molecular cancer research : MCR, 19(10), 1622-1634.

+ Open protocol

+ Expand

Cancer Drug Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Erlotinib, pazopanib, everolimus, mocetinostat, vorinostat, panobinostat were purchased (LC Laboratories, Woburn, USA). Regorafenib (BAY 73–4506) was provided by Bayer Pharma AG Germany, EPZ011898–9 by Epizyme (Cambridge, MA, USA). Compounds were dissolved in dimethylsulfoxide (DMSO) and stored in 10 mmol/L stock solutions. Recombinant hEGF (Cell Signaling, Saint Quentin Yvelines, France), recombinant hFGF basic, and recombinant hKGF/FGF7 (R&D Systems, Lille, France) were dissolved in PBS.

Harttrampf A.C., da Costa M.E., Renoult A., Daudigeos-Dubus E, & Geoerger B. (2021). Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. BMC Cancer, 21, 833.

+ Open protocol

+ Expand

Preparation of Pan-ERBB Inhibitor NT113

Check if the same lab product or an alternative is used in the 5 most similar protocols

NT113 is a quinazolinyl acrylamide based pan-ERBB irreversible inhibitor, and was provided by NewGen Therapeutics (Menlo Park, CA). For oral administration to animal subjects, NT113, as well as erlotinib and lapatinib (LC Laboratories, Woburn, MA), were dissolved in 2% N,N-Dimethylacetamide and 40% 2-Hydroxypropyl-beta-cyclodextrin at concentrations of 10, 100, and 150 mg/ml, respectively. For addition to cell cultures, stock solutions of NT113 and erlotinib were prepared by dissolution in dimethylsulfoxide (DMSO) at 10 mM.

Yoshida Y., Ozawa T., Yao T.W., Shen W., Brown D., Parsa A.T., Raizer J.J., Cheng S.Y., Stegh A.H., Mazar A.P., Giles F.J., Sarkaria J.N., Butowski N., Nicolaides T, & James C.D. (2014). NT113, a pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. Molecular cancer therapeutics, 13(12), 2919-2929.

+ Open protocol

+ Expand

Cell Line Characterization and MUC1 Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Detailed description can be found in Supplemental Materials and Methods for: cell line cultures conditions; antibodies and gRNA sequences used; MS instrument settings; in vivo PET imaging Cell lines, SILAC labeling, and reagents Human breast cancer cell lines SKBR3, BT474, BT549, and MDA-MB-231; human non-small cell lung cancer cell lines H292 and HCC827; and HEK-293T were obtained from American Type Culture Collection (ATCC). SUM149 cells were a gift from Prof. W.T.A. van der Graaf (Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands). Stable isotope labeling of cell lines (SILAC) was done using RPMI or DMEM-high glucose media with normal Arg and Lys (light) or Arg 10 and Lys 8 (heavy) (Silantes). Human MUC1 shedding was measured using a standardized MUC1 human ELISA kit (EHMUC1; Thermo Scientific), mouse MUC1 was measured using a MUC1 mouse ELISA kit (E-EL-M2604; Elabscience). MUC1 has a reported serum half-life of ~7 days 47 . The following inhibitors were used: EGFR inhibitors erlotinib (LC Laboratories; Axon Medchem), gefitinib (Axon Medchem), lapatinib (LC Laboratories), afatinib (Tocris); JAK2 inhibitor BMS-911543 (Selleckchem); PI3K inhibitor BEZ235, AKT inhibitor MK2206, mTORC1/2 inhibitor everolimus, ERK inhibitor FR18024, MEK1 inhibitor AZD6244 (Axon Medchem).

de Boer H.R., Pool M., Joosten E., Everts M., Samplonius D.F., Helfrich W., Groen H.J.M., van Cooten S., Fusetti F., Fehrmann R.S.N., de Vries E.G.E, & van Vugt M.A.T.M. (2019). Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 38(9).

+ Open protocol

+ Expand

Evaluating Kinase Inhibitors in CLL Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Gefitinib (LC Laboratories, Woburn, MA, USA), erlotinib (LC Laboratories), dasatinib (LC Laboratories), ibrutinib (SelleckBio, Houston, TX, USA), and fludarabine (Sigma, St. Louis, MO, USA) were all dissolved in DMSO (Thermo Fisher Scientific) and added. B cells were stimulated with 10 μg/ml biotinylated Fab₂'IgM (Southern Biotech, Birmingham, AL, USA) and T cells were stimulated with 2 μg/ml LEAF-purified anti-CD3 (BioLegend, San Diego, CA, USA). For western blot experiments, 10 μg/ml soluble anti-IgM was added and cells were lysed within 1 h. For cell death analysis after 24 h, 0.1 μg anti-IgM was immobilized in Hanks' buffered salt solution (HBSS, Life Technologies) in a 96-well Falcon plate (BD, Franklin Lakes, NJ, USA) overnight, and then washed before addition of CLL cells.

Dielschneider R.F., Xiao W., Yoon J.Y., Noh E., Banerji V., Li H., Marshall A.J., Johnston J.B, & Gibson S.B. (2014). Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death & Disease, 5(10), e1439-.

+ Open protocol

+ Expand

Tyrosine Kinase Inhibitor Dissolution

Check if the same lab product or an alternative is used in the 5 most similar protocols

Erlotinib, afatinib and rociletinib were purchased from LC Laboratories. Luminespib was purchased from Selleckchem. All reagents were dissolved in dimethyl sulfoxide and stored at −80°C.

Jorge S.E., Lucena-Araujo A.R., Yasuda H., Piotrowska Z., Oxnard G.R., Rangachari D., Huberman M.S., Sequist L.V., Kobayashi S.S, & Costa D.B. (2018). EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(24), 6548-6555.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!